Comparative Pharmacology
Head-to-head clinical analysis: PRED FORTE versus PREDNICEN M.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRED FORTE versus PREDNICEN M.
PRED FORTE vs PREDNICEN-M
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, causing inhibition of phospholipase A2, arachidonic acid release, and synthesis of inflammatory mediators. Reduces inflammation by suppressing leukocyte infiltration and cytokine production.
Prednicen-M is a glucocorticoid that binds to the glucocorticoid receptor (GR), leading to altered gene expression. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production (e.g., IL-1, IL-2, TNF-alpha). It also induces lipocortin synthesis, which inhibits arachidonic acid release.
1-2 drops in the conjunctival sac every 1-2 hours during the day and every 4 hours at night initially, then taper to every 4-8 hours as inflammation resolves. Severe cases may require hourly dosing.
Oral, 5-60 mg/day divided every 6-12 hours, adjusted based on disease severity and response.
None Documented
None Documented
2-3 hours (terminal) after IV administration; for topical ophthalmic use, systemic half-life is similar but local ocular half-life is prolonged due to corneal reservoir.
2-3 hours (prednisone); terminal half-life of prednisolone is 2-4 hours in normal renal function, prolonged to 3-4 hours in renal impairment, and may be extended in hepatic impairment.
Primarily hepatic metabolism; renal excretion of inactive metabolites accounts for approximately 80% of elimination, with biliary/fecal elimination <20%.
Renal: ~80% as metabolites and unchanged drug (primarily as 17-ketosteroids and glucuronide conjugates); fecal: <5%; biliary: minor.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Antibiotic Combination